These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 35982905)

  • 1. Development and application of ribonucleic acid therapy strategies against COVID-19.
    Ning L; Liu M; Gou Y; Yang Y; He B; Huang J
    Int J Biol Sci; 2022; 18(13):5070-5085. PubMed ID: 35982905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19.
    Bhavaniramya S; Ramar V; Vishnupriya S; Palaniappan R; Sibiya A; Vaseeharan B
    Curr Mol Pharmacol; 2022; 15(2):393-417. PubMed ID: 34382513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
    Dhankhar P; Dalal V; Kumar V
    J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Dhorne-Pollet S; Fitzpatrick C; Da Costa B; Bourgon C; Eléouët JF; Meunier N; Burzio VA; Delmas B; Barrey E
    Front Microbiol; 2022; 13():915202. PubMed ID: 36386681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID-19.
    Alavizadeh SH; Doagooyan M; Zahedipour F; Torghabe SY; Baharieh B; Soleymani F; Gheybi F
    IET Nanobiotechnol; 2022 May; 16(3):67-77. PubMed ID: 35274474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing aptamers against COVID-19: A therapeutic strategy.
    Mahmoudi A; Alavizadeh SH; Hosseini SA; Meidany P; Doagooyan M; Abolhasani Y; Saadat Z; Amani F; Kesharwani P; Gheybi F; Sahebkar A
    Drug Discov Today; 2023 Aug; 28(8):103663. PubMed ID: 37315763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.
    Yang N; Shen HM
    Int J Biol Sci; 2020; 16(10):1724-1731. PubMed ID: 32226290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics.
    Berber B; Aydin C; Kocabas F; Guney-Esken G; Yilancioglu K; Karadag-Alpaslan M; Caliseki M; Yuce M; Demir S; Tastan C
    Gene Ther; 2021 Jun; 28(6):290-305. PubMed ID: 33318646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targets and potential agents for the treatment of COVID-19.
    Wu Y; Li Z; Zhao YS; Huang YY; Jiang MY; Luo HB
    Med Res Rev; 2021 May; 41(3):1775-1797. PubMed ID: 33393116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide: A promising therapeutic option to beat COVID-19.
    Quemener AM; Galibert MD
    Wiley Interdiscip Rev RNA; 2022 Jul; 13(4):e1703. PubMed ID: 34842345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2.
    Wang SF; Chen KH; Wang SY; Yarmishyn AA; Lai WY; Lin YY; Wang ML; Chou SJ; Yang YP; Chang YL
    J Chin Med Assoc; 2020 Aug; 83(8):712-718. PubMed ID: 32433345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Hum C; Loiselle J; Ahmed N; Shaw TA; Toudic C; Pezacki JP
    Drugs; 2021 Apr; 81(5):517-531. PubMed ID: 33638807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
    Aftab SO; Ghouri MZ; Masood MU; Haider Z; Khan Z; Ahmad A; Munawar N
    J Transl Med; 2020 Jul; 18(1):275. PubMed ID: 32635935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.